Nanomedicine in Ophthalmology

Retina Fifth Edition

Volumn 1, Issue , 2012, Pages 689-715

  Zarbin, Marco A ^a   Leary, James F ^b   Montemagno, Carlo ^c   Ritch, Robert ^d,e   Humayun, Mark S ^f,g  

^a INSTITUTE OF OPHTHALMOLOGY AND VISUAL SCIENCE   (United States)

^b PURDUE UNIVERSITY   (United States)

^c 705 Engineering Research Center   (United States)

^d NEW YORK EYE AND EAR INFIRMARY   (United States)

^e NEW YORK MEDICAL COLLEGE   (United States)

^f UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^g DOHENY EYE INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84906796955     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-1-4557-0737-9.00036-9     Document Type: Chapter

References (312)

1. Haglund EM, Seale-Goldsmith M-M, Leary JF Design of multifunctional nanomedical systems. Ann Biomed Eng 2009, 37:2048-2063.
2. Seale M-M, Leary JF Nanobiosystems. WIREs Nanomed Nanobiotechnol 2009, 1:553-567.
3. Prow T, Grebe R, Merges C, et al. Nanoparticle tethered antioxidant response element as a biosensor for oxygen induced toxicity in retinal endothelial cells. Mol Vis 2006, 12:616-625.
4. Prow T, Smith JN, Grebe R, et al. Construction, gene delivery, and expression of DNA tethered nanoparticles. Mol Vis 2006, 12:606-615.
5. Zarbin MA, Montemagno C, Leary JF, et al. Nanomedicine in ophthalmology: the new frontier. Am J Ophthalmol 2010, 150:144-162.
6. Zarbin MA, Montemagno C, Leary JF, et al. Nanotechnology in ophthalmology. Can J Ophthalmol 2010, 45:457-476.
7. Zarbin MA, Montemagno C, Leary JF, et al. Regenerative nanomedicine and the treatment of degenerative retinal diseases. Wiley Interdiscip Rev Nanomed Nanobiotechnol 2012, 4:113-137.
8. Feynman R There's plenty of room at the bottom. Eng Sci 1960, 23:22-36.
9. Ball P High-density memory: a switch in time. Nature 2007, 445:362-363.
10. Soong RK, Bachand GD, Neves HP, et al. Powering an inorganic nanodevice with a biomolecular motor. Science 2000, 290:1555-1558.
11. Freitas RA What is nanomedicine?. Nanomedicine 2005, 1:2-9.
12. Morrow KJ, Bawa R, Wei C Recent advances in basic and clinical nanomedicine. Medical Clin North Am 2007, 91:805-843.
13. Prow T, Salazar JH, Rose WA, et al. Nanomedicine - nanoparticles, molecular biosensors and targeted gene/drug delivery for combined single-cell diagnostics and therapeutics. Proc SPIE 2004, 5318:1-11.
14. Prow T, Rose WA, Wang NA, et al. Biosensor-controlled gene therapy/drug delivery with nanoparticles for nanomedicine. Proc SPIE 2005, 5692:199-208.
15. Seale M, Haglund E, Cooper CL, et al. Design of programmable multilayered nanoparticles with in situ manufacture of therapeutic genes for nanomedicine. Proc SPIE 2007, 6430. 643003-1-7.
16. Banghart M, Borges K, Isacoff E, et al. Light-activated ion channels for remote control of neuronal firing. Nat Neurosci 2004, 7:1381-1386.
17. Volgraf M, Gorostiza P, Numano R, et al. Allosteric control of an ionotropic glutamate receptor with an optical switch. Nature Chem Biol 2006, 2:47-52.
18. Szobota S, Gorostiza P, Del Bene F, et al. Remote control of neuronal activity with a light-gated glutamate receptor. Neuron 2007, 54:535-545.
19. Barnes CP, Sell SA, Boland ED, et al. Nanofiber technology: designing the next generation of tissue engineering scaffolds. Adv Drug Deliv Rev 2007, 59:1413-1433.
20. Causa F, Netti PA, Ambrosio L A multi-functional scaffold for tissue regeneration: The need to engineer a tissue analogue. Biomaterials 2007, 28:5093-5099.
21. Goldberg M, Langer R, Jia X Nanostructured materials for applications in drug delivery and tissue engineering. J Biomat Sci 2007, 18:241-268.
22. Quondamatteo F Assembly, stability and integrity of basement membranes in vivo. Histochem J 2002, 34:369-381.
23. Weigel T, Schinkel G, Lendlein A Design and preparation of polymeric scaffolds for tissue engineering. Exp Rev Med Devices 2006, 3:835-851.
24. Sretavan DW, Chang W, Hawkes E, et al. Microscale surgery on single axons. Neurosurgery 2005, 57:635-646. discussion 646.
25. Tao S, Young C, Redenti S, et al. Survival, migration and differentiation of retinal progenitor cells transplanted on micro-machined poly(methyl methacrylate) scaffolds to the subretinal space. Lab on a chip 2007, 7:695-701.
26. Ferreira L, Karp JM, Nobre L, et al. New opportunities: the use of nanotechnologies to manipulate and track stem cells. Cell Stem Cell 2008, 3:136-146.
27. Montemagno CD Integrative technology for the twenty-first century. Ann N Y Acad Sci 2004, 1013:38-49.
28. Wendell DW, Patti J, Montemagno CD Using biological inspiration to engineer functional nanostructured materials. Small 2006, 2:1324-1329.
29. Wendell D, Todd J, Montemagno C Artificial photosynthesis in ranaspumin-2 based foam. Nano Lett 2010, 10:3231-3236.
30. Liu H, Schmidt JJ, Bachand GD, et al. Control of a biomolecular motor-powered nanodevice with an engineered chemical switch. Nat Mater 2002, 1:173-177.
31. Xi J, Schmidt JJ, Montemagno CD Self-assembled microdevices driven by muscle. Nat Mater 2005, 4:180-184.
32. Bachand GD, Montemagno CD Constructing organic/inorganic NEMS devices powered by biomolecular motors. Biomed Microdevices 2000, 3:179-184. 2.
33. Ainslie KM, Tao SL, Popat KC, et al. In vitro immunogenicity of silicon-based micro- and nanostructured surfaces. ACS Nano 2008, 2:1076-1084.
34. Curtis AS, Gadegaard N, Dalby MJ, et al. Cells react to nanoscale order and symmetry in their surroundings. IEEE Trans Nanobiosci 2004, 3:61-65.
35. Dalby MJ, Riehle MO, Sutherland DS, et al. Changes in fibroblast morphology in response to nano-columns produced by colloidal lithography. Biomaterials 2004, 25:5415-5422.
36. Gallagher JO, McGhee KF, Wilkinson CD, et al. Interaction of animal cells with ordered nanotopography. IEEE Trans Nanobiosci 2002, 1:24-28.
37. Huang NF, Patel S, Thakar RG, et al. Myotube assembly on nanofibrous and micropatterned polymers. Nano Lett 2006, 6:537-542.
38. Kim DHK, Suh KY, Choi SK, et al. Modulation of adhesion and growth of cardiac myocytes by surface nanotopography 2005, 27th Annual International Conference of the Engineering in Medicine and Biology Society, p. 4091-4.
39. Popat KC, Leoni L, Grimes CA, et al. Influence of engineered titania nanotubular surfaces on bone cells. Biomaterials 2007, 28:3188-3197.
40. Yim EK, Reano RM, Pang SW, et al. Nanopattern-induced changes in morphology and motility of smooth muscle cells. Biomaterials 2005, 26:5405-5413.
41. Lin YM, Avouris P Strong suppression of electrical noise in bilayer graphene nanodevices. Nano Lett 2008, 8:2119-2125.
42. Deshpande S, Patil S, Kuchibhatla SV, et al. Size dependency variation in lattice parameter and valency states in nanocrystalline cerium oxide. Appl Phys Lett 2005, 87:133113.
43. Tsunekawa S, Sahara R, Kawazoe Y, et al. Lattice relaxation of monosize CeO2-x nanocrystalline particles. Appl Surface Sci 1999, 152:53-56.
44. Yanik MF, Cinar H, Cinar HN, et al. Neurosurgery: functional regeneration after laser axotomy. Nature 2004, 432:822.
45. Wei C, Wei W, Morris M, et al. Nanomedicine and drug delivery. Exp Rev Med Devices 2007, 91:863-870.
46. Dresher RP, Irazoqui PP A compact nanopower low output impedance CMOS operational amplifier for wireless intraocular pressure recordings. Conf Proc IEEE Eng Med Biol Soc 2007, 2007:6056-6059.
47. Pan T, Brown JD, Ziaie B An artificial nano-drainage implant (ANDI) for glaucoma treatment. Conf Proc IEEE Eng Med Biol Soc 2006, 1:3174-3177.
48. Chu TC, He Q, Potter DE Biodegradable calcium phosphate nanoparticles as a new vehicle for delivery of a potential ocular hypotensive agent. J Ocul Pharmacol Ther 2002, 18:507-514.
49. Kassem MA, Abdel Rahman AA, Ghorab MM, et al. Nanosuspension as an ophthalmic delivery system for certain glucocorticoid drugs. Int J Pharm 2007, 340:126-133.
50. Kim W, Ng JK, Kunitake ME, et al. Interfacing silicon nanowires with mammalian cells. J Am Chem Soc 2007, 129:7228-7229.
51. Kostarelos K, Lacerda L, Pastorin G, et al. Cellular uptake of functionalized carbon nanotubes is independent of functional group and cell type. Nature nanotechnol 2007, 2:108-113.
52. Bianco A, Kostarelos K, Prato M Applications of carbon nanotubes in drug delivery. Curr opin chem biol 2005, 9:674-679.
53. Petros RA, DeSimone JM Strategies in the design of nanoparticles for therapeutic applications. Nature rev 2010, 9:615-627.
54. Rejman J, Oberle V, Zuhorn IS, et al. Size-dependent internalization of particles via the pathways of clathrin- and caveolae-mediated endocytosis. Biochem J 2004, 377:159-169.
55. Chen X, Kube DM, Cooper MJ, et al. Cell surface nucleolin serves as receptor for DNA nanoparticles composed of pegylated polylysine and DNA. Mol Ther 2008, 16:333-342.
56. Renschler MF, Bhatt RR, Dower WJ, et al. Synthetic peptide ligands of the antigen binding receptor induce programmed cell death in a human B-cell lymphoma. Proc Natl Acad Sci U S A 1994, 91:3623-3627.
57. Bareford LM, Swaan PW Endocytic mechanisms for targeted drug delivery. Adv Drug Deliv Rev 2007, 59:748-758.
58. Torchilin VP Cell penetrating peptide-modified pharmaceutical nanocarriers for intracellular drug and gene delivery. Biopolymers 2008, 90:604-610.
59. Kirpotin D, Hong K, Mullah N, et al. Liposomes with detachable polymer coating: destabilization and fusion of dioleoylphosphatidylethanolamine vesicles triggered by cleavage of surface-grafted poly(ethylene glycol). FEBS Lett 1996, 388:115-118.
60. Saito G, Swanson JA, Lee KD Drug delivery strategy utilizing conjugation via reversible disulfide linkages: role and site of cellular reducing activities. Adv Drug Deliv Rev 2003, 55:199-215.
61. Boddapati SV, D'Souza GG, Erdogan S, et al. Organelle-targeted nanocarriers: specific delivery of liposomal ceramide to mitochondria enhances its cytotoxicity in vitro and in vivo. Nano Lett 2008, 8:2559-2563.
62. Wagstaff KM, Jans DA Importins and beyond: non-conventional nuclear transport mechanisms. Traffic (Copenhagen, Denmark) 2009, 10:1188-1198.
63. Moghimi SM, Hamad I, Andresen TL, et al. Methylation of the phosphate oxygen moiety of phospholipid-methoxy(polyethylene glycol) conjugate prevents PEGylated liposome-mediated complement activation and anaphylatoxin production. FASEB J 2006, 20:2591-2593.
64. Hamad I, Christy Hunter A, Rutt KJ, et al. Complement activation by PEGylated single-walled carbon nanotubes is independent of C1q and alternative pathway turnover. Mol Immunol 2008, 45:3797-3803.
65. Yokoe J, Sakuragi S, Yamamoto K, et al. Albumin-conjugated PEG liposome enhances tumor distribution of liposomal doxorubicin in rats. Int J Pharm 2008, 353:28-34.
66. Furumoto K, Yokoe J, Ogawara K, et al. Effect of coupling of albumin on to surface of PEG liposome on its in vivo disposition. Int J Pharm 2007, 329:110-116.
67. Tomalia DA, Reyna LA, Svenson S Dendrimers as multi-purpose nanodevices for oncology drug delivery and diagnostic imaging. Biochem Soc Trans 2007, 35:61-67.
68. Hahn U, Gorka M, Vogtle F, et al. Light-harvesting dendrimers: efficient intra- and intermolecular energy-transfer processes in a species containing 65 chromophoric groups of four different types. Angew Chem Int Ed Engl 2002, 41:3595-3598. 14.
69. Durairaj C, Kadam RS, Chandler JW, et al. Nanosized dendritic polyguanidilyated translocators for enhanced solubility, permeability, and delivery of gatifloxacin. Invest Ophthalmol Vis Sci 2010, 51:5804-5816.
70. Marano RJ, Toth I, Wimmer N, et al. Dendrimer delivery of an anti-VEGF oligonucleotide into the eye: a long-term study into inhibition of laser-induced CNV, distribution, uptake and toxicity. Gene Ther 2005, 12:1544-1550.
71. Vandamme TF, Brobeck L Poly(amidoamine) dendrimers as ophthalmic vehicles for ocular delivery of pilocarpine nitrate and tropicamide. J Control Release 2005, 102:23-38.
72. Kang SJ, Durairaj C, Kompella UB, et al. Subconjunctival nanoparticle carboplatin in the treatment of murine retinoblastoma. Arch Ophthalmol 2009, 127:1043-1047.
73. Ideta R, Tasaka F, Jang WD, et al. Nanotechnology-based photodynamic therapy for neovascular disease using a supramolecular nanocarrier loaded with a dendritic photosensitizer. Nano Lett 2005, 5:2426-2431.
74. Shaunak S, Thomas S, Gianasi E, et al. Polyvalent dendrimer glucosamine conjugates prevent scar tissue formation. Nat Biotechnol 2004, 22:977-984.
75. Mead AL, Wong TT, Cordeiro MF, et al. Evaluation of anti-TGF-beta2 antibody as a new postoperative anti-scarring agent in glaucoma surgery. Invest Ophthalmol Vis Sci 2003, 44:3394-3401.
76. Siriwardena D, Khaw PT, King AJ, et al. Human antitransforming growth factor beta(2) monoclonal antibody - a new modulator of wound healing in trabeculectomy: a randomized placebo controlled clinical study. Ophthalmology 2002, 109:427-431.
77. Ferreira L, Park H, Choe H, et al. Human embryoid bodies containing nano- and micro-particulate delivery vehicles. Adv Mat 2008, 20:2285-2291.
78. Sakai T, Kuno N, Takamatsu F, et al. Prolonged protective effect of basic fibroblast growth factor-impregnated nanoparticles in Royal College of Surgeons rats. Invest Ophthalmol Vis Sci 2007, 48:3381-3387.
79. Vollrath D, Feng W, Duncan JL, et al. Correction of the retinal dystrophy phenotype of the RCS rat by viral gene transfer of Mertk. Proc Natl Acad Sci U S A 2001, 98:12584-12589.
80. Gal A, Li Y, Thompson DA, et al. Mutations in MERTK, the human orthologue of the RCS rat retinal dystrophy gene, cause retinitis pigmentosa. Nat Genet 2000, 26:270-271.
81. Charbel Issa P, Bolz HJ, Ebermann I, et al. Characterisation of severe rod-cone dystrophy in a consanguineous family with a splice site mutation in the MERTK gene. Br J Ophthalmol 2009, 93:920-925.
82. Mackay DS, Henderson RH, Sergouniotis PI, et al. Novel mutations in MERTK associated with childhood onset rod-cone dystrophy. Mol Vis 2010, 16:369-377.
83. Quigley HA, Broman AT The number of people with glaucoma worldwide in 2010 and 2020. Br J Ophthalmol 2006, 90:262-267.
84. Jiang C, Moore MJ, Zhang X, et al. Intravitreal injections of GDNF-loaded biodegradable microspheres are neuroprotective in a rat model of glaucoma. Mol Vis 2007, 13:1783-1792.
85. Fu K, Harrell R, Zinski K, et al. A potential approach for decreasing the burst effect of protein from PLGA microspheres. J Pharm Sci 2003, 92:1582-1591.
86. Dalkara D, Kolstad KD, Guerin KI, et al. AAV mediated GDNF secretion from retinal glia slows down retinal degeneration in a rat model of retinitis pigmentosa. Mol Ther 2011, 19:1602-1608.
87. Brownlee M A radical explanation for glucose-induced beta cell dysfunction. J Clin Invest 2003, 112:1788-1790.
88. Yorek MA The role of oxidative stress in diabetic vascular and neural disease. Free Radic Res 2003, 37:471-480.
89. Dugan LL, Lovett EG, Quick KL, et al. Fullerene-based antioxidants and neurodegenerative disorders. Parkinsonism Relat Disord 2001, 7:243-246.
90. Shen JK, Dong A, Hackett SF, et al. Oxidative damage in age-related macular degeneration. Histol Histopathol 2007, 22:1301-1308.
91. Komeima K, Rogers BS, Campochiaro PA Antioxidants slow photoreceptor cell death in mouse models of retinitis pigmentosa. J Cell Physiol 2007, 213:809-815.
92. Papp A, Nemeth I, Karg E, et al. Glutathione status in retinopathy of prematurity. Free Radic Biol Med 1999, 27:738-743.
93. Chen J, Patil S, Seal S, et al. Rare earth nanoparticles prevent retinal degeneration induced by intracellular peroxides. Nat Nanotechnol 2006, 1:142-150.
94. Zhou X, Wong LL, Karakoti AS, et al. Nanoceria inhibit the development and promote the regression of pathologic retinal neovascularization in the Vldlr knockout mouse. PLoS ONE 2011, 6:e16733.
95. Truong SN, Alam S, Zawadzki RJ, et al. High resolution Fourier-domain optical coherence tomography of retinal angiomatous proliferation. Retina 2007, 27:915-925.
96. Elman MJ, Aiello LP, Beck RW, et al. Randomized trial evaluating ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema. Ophthalmology 2010, 117:1064-1077. e35.
97. Rosenfeld PJ, Brown DM, Heier JS, et al. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 2006, 355:1419-1431.
98. Brown DM, Kaiser PK, Michels M, et al. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med 2006, 355:1432-1444.
99. Kroto HW, Heath JR, O'Brien SC, et al. C60: Buckminsterfullerene. Nature 1985, 318:162-163.
100. Dugan LL, Turetsky DM, Du C, et al. Carboxyfullerenes as neuroprotective agents. Proc Natl Acad Sci U S A 1997, 94:9434-9439.
101. Shichi H Microsomal electron transfer system of bovine retinal pigment epithelium. Exp Eye Res 1969, 8:60-68.
102. Yau KW, Baylor DA Cyclic GMP-activated conductance of retinal photoreceptor cells. Annu Rev Neurosci 1989, 12:289-327.
103. Moiseyev G, Chen Y, Takahashi Y, et al. RPE65 is the isomerohydrolase in the retinoid visual cycle. Proc Natl Acad Sci U S A 2005, 102:12413-12418.
104. Halliwell B, Gutteridge JM Oxygen toxicity, oxygen radicals, transition metals and disease. Biochem J 1984, 219:1-14.
105. Rogers BS, Symons RC, Komeima K, et al. Differential sensitivity of cones to iron-mediated oxidative damage. Invest Ophthalmol Vis Sci 2007, 48:438-445.
106. Liu G, Men P, Harris PL, et al. Nanoparticle iron chelators: a new therapeutic approach in Alzheimer disease and other neurologic disorders associated with trace metal imbalance. Neurosci Lett 2006, 406:189-193.
107. Hahn P, Milam AH, Dunaief JL Maculas affected by age-related macular degeneration contain increased chelatable iron in the retinal pigment epithelium and Bruch's membrane. Arch Ophthalmol 2003, 121:1099-1105.
108. Hahn P, Qian Y, Dentchev T, et al. Disruption of ceruloplasmin and hephaestin in mice causes retinal iron overload and retinal degeneration with features of age-related macular degeneration. Proc Natl Acad Sci U S A 2004, 101:13850-13855.
109. Dunaief JL, Richa C, Franks EP, et al. Macular degeneration in a patient with aceruloplasminemia, a disease associated with retinal iron overload. Ophthalmology 2005, 112:1062-1065.
110. Chowers I, Wong R, Dentchev T, et al. The iron carrier transferrin is upregulated in retinas from patients with age-related macular degeneration. Invest Ophthalmol Vis Sci 2006, 47:2135-2140.
111. He X, Hahn P, Iacovelli J, et al. Iron homeostasis and toxicity in retinal degeneration. Prog Retin Eye Res 2007, 26:649-673.
112. Gullapalli VKKM, Wang H, Sugino IK, et al. Retinal pigment epithelium and photoreceptor transplantation frontiers. Retina 2006, 2597-2613. Mosby, Philadelphia, PA. 4th ed. S.J. Ryan (Ed.).
113. Zarbin MA Functionalizing cell-based therapy for age-related macular degeneration. Am J Ophthalmol 2007, 143:681-682.
114. Zarbin MA Retinal pigment epithelium-retina transplantation for retinal degenerative disease. Am J Ophthalmol 2008, 146:151-153.
115. Yuan XB, Yuan YB, Jiang W, et al. Preparation of rapamycin-loaded chitosan/PLA nanoparticles for immunosuppression in corneal transplantation. Int J Pharm 2008, 349:241-248.
116. Prow TW, Bhutto I, Kim SY, et al. Ocular nanoparticle toxicity and transfection of the retina and retinal pigment epithelium. Nanomedicine 2008, 4:340-349.
117. Caspi RR Experimental autoimmune uveoretinitis in the rat and mouse. Curr Protoc Immunol 2003, Chapter 15:Unit 15 6.
118. Sakai T, Kohno H, Ishihara T, et al. Treatment of experimental autoimmune uveoretinitis with poly(lactic acid) nanoparticles encapsulating betamethasone phosphate. Exp Eye Res 2006, 82:657-663.
119. Bazile D, Prud'homme C, Bassoullet MT, et al. Stealth Me.PEG-PLA nanoparticles avoid uptake by the mononuclear phagocytes system. J Pharm Sci 1995, 84:493-498.
120. Ishihara T, Kubota T, Choi T, et al. Polymeric nanoparticles encapsulating betamethasone phosphate with different release profiles and stealthiness. Int J Pharm 2009, 375:148-154.
121. Sakai T, Ishihara T, Higaki M, et al. Therapeutic effect of stealth-type polymeric nanoparticles with encapsulated betamethasone phosphate on experimental autoimmune uveoretinitis. Invest Ophthalmol Vis Sci 2011, 52:1516-1521.
122. Zhang R, He R, Qian J, et al. Treatment of experimental autoimmune uveoretinitis with intravitreal injection of tacrolimus (FK506) encapsulated in liposomes. Invest Ophthalmol Vis Sci 2010, 51:3575-3582.
123. Glover DJ, Lipps HJ, Jans DA Towards safe, non-viral therapeutic gene expression in humans. Nat Rev Genet 2005, 6:299-310.
124. Kutsuzawa K, Chowdhury EH, Nagaoka M, et al. Surface functionalization of inorganic nano-crystals with fibronectin and E-cadherin chimera synergistically accelerates trans-gene delivery into embryonic stem cells. Biochem Biophys Res Commun 2006, 350:514-520.
125. Mo Y, Barnett ME, Takemoto D, et al. Human serum albumin nanoparticles for efficient delivery of Cu, Zn superoxide dismutase gene. Mol Vis 2007, 13:746-757.
126. Cai X, Conley S, Naash M Nanoparticle applications in ocular gene therapy. Vision Res 2008, 48:319-324.
127. Farjo R, Skaggs J, Quiambao AB, et al. Efficient non-viral ocular gene transfer with compacted DNA nanoparticles. PLoS ONE 2006, 1:e38.
128. Pack DW, Hoffman AS, Pun S, et al. Design and development of polymers for gene delivery. Nat Rev 2005, 4:581-593.
129. Incani V, Tunis E, Clements BA, et al. Palmitic acid substitution on cationic polymers for effective delivery of plasmid DNA to bone marrow stromal cells. J Biomed Mater Res A 2007, 81:493-504.
130. Konstan MW, Davis PB, Wagener JS, et al. Compacted DNA nanoparticles administered to the nasal mucosa of cystic fibrosis subjects are safe and demonstrate partial to complete cystic fibrosis transmembrane regulator reconstitution. Hum Gene Ther 2004, 15:1255-1269.
131. Pitkanen L, Ruponen M, Nieminen J, et al. Vitreous is a barrier in nonviral gene transfer by cationic lipids and polymers. Pharm Res 2003, 20:576-583.
132. Cai X, Conley SM, Nash Z, et al. Gene delivery to mitotic and postmitotic photoreceptors via compacted DNA nanoparticles results in improved phenotype in a mouse model of retinitis pigmentosa. FASEB J 2010, 24:1178-1191.
133. Flannery JGZS, Vaquero MI, LaVail MM, et al. Efficient photoreceptor-targeted gene expression in vivo by recombinant adeno-associated virus. Proc Natl Acad Sci U S A 1997, 94:6916-6921.
134. Li Q, Timmers AM, Guy J, et al. Cone-specific expression using a human red opsin promoter in recombinant AAV. Vision Res 2008, 48:332-338.
135. Porrello K, Bhat SP, Bok D Detection of interphotoreceptor retinoid binding protein (IRBP) mRNA in human and cone-dominant squirrel retinas by in situ hybridization. J Histochem Cytochem 1991, 39:171-176.
136. Esumi N, Oshima Y, Li Y, et al. Analysis of the VMD2 promoter and implication of E-box binding factors in its regulation. J Biol Chem 2004, 279:19064-19073.
137. Cai X, Nash Z, Conley SM, et al. A partial structural and functional rescue of a retinitis pigmentosa model with compacted DNA nanoparticles. PLoS ONE 2009, 4:e5290.
138. Bejjani RA, BenEzra D, Cohen H, et al. Nanoparticles for gene delivery to retinal pigment epithelial cells. Mol Vis 2005, 11:124-132.
139. Conley SM, Cai X, Naash MI Nonviral ocular gene therapy: assessment and future directions. Curr Opin Mol Ther 2008, 10:456-463.
140. Conley SM, Naash MI Nanoparticles for retinal gene therapy. Prog Retin Eye Res 2010, 29:376-397.
141. Ravi Kumar MN, Bakowsky U, Lehr CM Preparation and characterization of cationic PLGA nanospheres as DNA carriers. Biomaterials 2004, 25:1771-1777.
142. Marmorstein AD, Marmorstein LY, Rayborn M, et al. Bestrophin, the product of the Best vitelliform macular dystrophy gene (VMD2), localizes to the basolateral plasma membrane of the retinal pigment epithelium. Proc Natl Acad Sci U S A 2000, 97:12758-12763.
143. Maguire AM, Simonelli F, Pierce EA, et al. Safety and efficacy of gene transfer for Leber's congenital amaurosis. N Engl J Med 2008, 358:2240-2248.
144. Bainbridge JW, Smith AJ, Barker SS, et al. Effect of gene therapy on visual function in Leber's congenital amaurosis. N Engl J Med 2008, 358:2231-2239.
145. Cideciyan AV, Hauswirth WW, Aleman TS, et al. Human RPE65 gene therapy for Leber congenital amaurosis: persistence of early visual improvements and safety at 1 year. Hum Gene Ther 2009, 20:999-1004.
146. Jani PD, Singh N, Jenkins C, et al. Nanoparticles sustain expression of Flt intraceptors in the cornea and inhibit injury-induced corneal angiogenesis. Invest Ophthalmol Vis Sci 2007, 48:2030-2036.
147. Kay MA State-of-the-art gene-based therapies: the road ahead. Nat Rev Genet 2011, 12:316-328.
148. Donsante A, Miller DG, Li Y, et al. AAV vector integration sites in mouse hepatocellular carcinoma. Science 2007, 317:477.
149. Hacein-Bey-Abina S, Von Kalle C, Schmidt M, et al. LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1. Science 2003, 302:415-419.
150. Boutin S, Monteilhet V, Veron P, et al. Prevalence of serum IgG and neutralizing factors against adeno-associated virus (AAV) types 1, 2, 5, 6, 8, and 9 in the healthy population: implications for gene therapy using AAV vectors. Hum Gene Ther 2010, 21:704-712.
151. Erles K, Sebokova P, Schlehofer JR Update on the prevalence of serum antibodies (IgG and IgM) to adeno-associated virus (AAV). J Med Virol 1999, 59:406-411.
152. Raper SE, Chirmule N, Lee FS, et al. Fatal systemic inflammatory response syndrome in a ornithine transcarbamylase deficient patient following adenoviral gene transfer. Mol Genet Metab 2003, 80:148-158.
153. Zaiss AK, Machado HB, Herschman HR The influence of innate and pre-existing immunity on adenovirus therapy. J Cell Biochem 2009, 108:778-790.
154. Manno CS, Pierce GF, Arruda VR, et al. Successful transduction of liver in hemophilia by AAV-factor IX and limitations imposed by the host immune response. Nat Med 2006, 12:342-347.
155. Mingozzi F, Maus MV, Hui DJ, et al. CD8(+) T-cell responses to adeno-associated virus capsid in humans. Nat Med 2007, 13:419-422.
156. Petry H, Brooks A, Orme A, et al. Effect of viral dose on neutralizing antibody response and transgene expression after AAV1 vector re-administration in mice. Gene Ther 2008, 15:54-60.
157. Hauswirth WW, Aleman TS, Kaushal S, et al. Treatment of Leber congenital amaurosis due to RPE65 mutations by ocular subretinal injection of adeno-associated virus gene vector: short-term results of a phase I trial. Hum Gene Ther 2008, 19:979-990.
158. Goncalves MA Adeno-associated virus: from defective virus to effective vector. Virol J 2005, 2:43.
159. Surace EM, Auricchio A Versatility of AAV vectors for retinal gene transfer. Vision Res 2008, 48:353-359.
160. Yang GS, Schmidt M, Yan Z, et al. Virus-mediated transduction of murine retina with adeno-associated virus: effects of viral capsid and genome size. J Virol 2002, 76:7651-7660.
161. Zaiss AK, Muruve DA Immunity to adeno-associated virus vectors in animals and humans: a continued challenge. Gene Ther 2008, 15:808-816.
162. Sun JY, Anand-Jawa V, Chatterjee S, et al. Immune responses to adeno-associated virus and its recombinant vectors. Gene Ther 2003, 10:964-976.
163. Ivics Z, Izsvak Z The expanding universe of transposon technologies for gene and cell engineering. Mob DNA 2010, 1:25.
164. Calos MP The phiC31 integrase system for gene therapy. Curr Gene Ther 2006, 6:633-645.
165. Kwon I, Schaffer DV Designer gene delivery vectors: molecular engineering and evolution of adeno-associated viral vectors for enhanced gene transfer. Pharm Res 2008, 25:489-499.
166. Maheshri N, Koerber JT, Kaspar BK, et al. Directed evolution of adeno-associated virus yields enhanced gene delivery vectors. Nat Biotechnol 2006, 24:198-204.
167. Zhao H, Giver L, Shao Z, et al. Molecular evolution by staggered extension process (StEP) in vitro recombination. Nat Biotechnol 1998, 16:258-261.
168. Koerber JT, Klimczak R, Jang JH, et al. Molecular evolution of adeno-associated virus for enhanced glial gene delivery. Mol Ther 2009, 17:2088-2095.
169. Klimczak RR, Koerber JT, Dalkara D, et al. A novel adeno-associated viral variant for efficient and selective intravitreal transduction of rat Müller cells. PLoS ONE 2009, 4:e7467.
170. LaVail MM, Yasumura D, Matthes MT, et al. Protection of mouse photoreceptors by survival factors in retinal degenerations. Invest Ophthalmol Vis Sci 1998, 39:592-602.
171. Chaum E Retinal neuroprotection by growth factors: a mechanistic perspective. J Cell Biochem 2003, 88:57-75.
172. Sieving PA, Caruso RC, Tao W, et al. Ciliary neurotrophic factor (CNTF) for human retinal degeneration: phase I trial of CNTF delivered by encapsulated cell intraocular implants. Proc Natl Acad Sci U S A 2006, 103:3896-3901.
173. Zhong L, Li B, Mah CS, et al. Next generation of adeno-associated virus 2 vectors: point mutations in tyrosines lead to high-efficiency transduction at lower doses. Proc Natl Acad Sci U S A 2008, 105:7827-7832.
174. Wang W, Malcolm BA Two-stage PCR protocol allowing introduction of multiple mutations, deletions and insertions using QuikChange site-directed mutagenesis. Biotechniques 1999, 26:680-682.
175. Zhong L, Zhao W, Wu J, et al. A dual role of EGFR protein tyrosine kinase signaling in ubiquitination of AAV2 capsids and viral second-strand DNA synthesis. Mol Ther 2007, 15:1323-1330.
176. Mah C, Qing K, Khuntirat B, et al. Adeno-associated virus type 2-mediated gene transfer: role of epidermal growth factor receptor protein tyrosine kinase in transgene expression. J Virol 1998, 72:9835-9843.
177. Zhong L, Zhou X, Li Y, et al. Single-polarity recombinant adeno-associated virus 2 vector-mediated transgene expression in vitro and in vivo: mechanism of transduction. Mol Ther 2008, 16:290-295.
178. McCarty DM, Fu H, Monahan PE, et al. Adeno-associated virus terminal repeat (TR) mutant generates self-complementary vectors to overcome the rate-limiting step to transduction in vivo. Gene Ther 2003, 10:2112-2118.
179. Yokoi K, Kachi S, Zhang HS, et al. Ocular gene transfer with self-complementary AAV vectors. Invest Ophthalmol Vis Sci 2007, 48:3324-3328.
180. Acland GM, Aguirre GD, Bennett J, et al. Long-term restoration of rod and cone vision by single dose rAAV-mediated gene transfer to the retina in a canine model of childhood blindness. Mol Ther 2005, 12:1072-1082.
181. Min SH, Molday LL, Seeliger MW, et al. Prolonged recovery of retinal structure/function after gene therapy in an Rs1h-deficient mouse model of X-linked juvenile retinoschisis. Mol Ther 2005, 12:644-651.
182. Petrs-Silva H, Dinculescu A, Li Q, et al. High-efficiency transduction of the mouse retina by tyrosine-mutant AAV serotype vectors. Mol Ther 2009, 17:463-471.
183. Streilein JW Limitations in the study of immune privilege in the subretinal space of the rodent. Invest Ophthalmol Vis Sci 1999, 40:3069.
184. Li Q, Miller R, Han PY, et al. Intraocular route of AAV2 vector administration defines humoral immune response and therapeutic potential. Mol Vis 2008, 14:1760-1769.
185. Nune SK, Gunda P, Thallapally PK, et al. Nanoparticles for biomedical imaging. Exp Opin Drug Deliv 2009, 6:1175-1194.
186. Boisselier E, Astruc D Gold nanoparticles in nanomedicine: preparations, imaging, diagnostics, therapies and toxicity. Chem Soc Rev 2009, 38:1759-1782.
187. Elghanian R, Storhoff JJ, Mucic RC, et al. Selective colorimetric detection of polynucleotides based on the distance-dependent optical properties of gold nanoparticles. Science 1997, 277:1078-1081.
188. Reimer P, Balzer T Ferucarbotran (Resovist): a new clinically approved RES-specific contrast agent for contrast-enhanced MRI of the liver: properties, clinical development, and applications. Eur Radiol 2003, 13:1266-1276.
189. Wang YX, Hussain SM, Krestin GP Superparamagnetic iron oxide contrast agents: physicochemical characteristics and applications in MR imaging. Eur Radiol 2001, 11:2319-2331.
190. Hsiao JK, Tai MF, Chu HH, et al. Magnetic nanoparticle labeling of mesenchymal stem cells without transfection agent: cellular behavior and capability of detection with clinical 1.5 T magnetic resonance at the single cell level. Magn Reson Med 2007, 58:717-724.
191. Zhu J, Zhou L, XingWu F Tracking neural stem cells in patients with brain trauma. N Engl J Med 2006, 355:2376-2378.
192. Guzman R, Uchida N, Bliss TM, et al. Long-term monitoring of transplanted human neural stem cells in developmental and pathological contexts with MRI. Proc Natl Acad Sci U S A 2007, 104:10211-10216.
193. Michalet X, Pinaud FF, Bentolila LA, et al. Quantum dots for live cells, in vivo imaging, and diagnostics. Science 2005, 307:538-544.
194. Lei Y, Tang H, Yao L, et al. Applications of mesenchymal stem cells labeled with Tat peptide conjugated quantum dots to cell tracking in mouse body. Bioconjugate Chem 2008, 19:421-427.
195. Slotkin JR, Chakrabarti L, Dai HN, et al. In vivo quantum dot labeling of mammalian stem and progenitor cells. Dev Dyn 2007, 236:3393-3401.
196. Derfus AM, Chan WCW, Bhatia SN Probing the cytotoxicity of semiconductor quantum dots. Adv Mat 2004, 4:11-18.
197. Lovric J, Cho SJ, Winnik FM, et al. Unmodified cadmium telluride quantum dots induce reactive oxygen species formation leading to multiple organelle damage and cell death. Chem Biol 2005, 12:1227-1234.
198. Zarbin MA Current concepts in the pathogenesis of age-related macular degeneration. Arch Ophthalmol 2004, 122:598-614.
199. Takeda A, Baffi JZ, Kleinman ME, et al. CCR3 is a target for age-related macular degeneration diagnosis and therapy. Nature 2009, 460:225-230.
200. Cohen-Karni T, Timko BP, Weiss LE, et al. Flexible electrical recording from cells using nanowire transistor arrays. Proc Natl Acad Sci U S A 2009, 106:7309-7313.
201. Graham SL, Drance SM Nocturnal hypotension: role in glaucoma progression. Surv Ophthalmol 1999, 43(Suppl 1):S10-S16.
202. Barkana Y, Anis S, Liebmann J, et al. Clinical utility of intraocular pressure monitoring outside of normal office hours in patients with glaucoma. Arch Ophthalmol 2006, 124:793-797.
203. Wax MB, Camras CB, Fiscella RG, et al. Emerging perspectives in glaucoma: optimizing 24-hour control of intraocular pressure. Am J Ophthalmol 2002, 133 Suppl:S1-10.
204. Lee GA, Khaw PT, Ficker LA, et al. The corneal thickness and intraocular pressure story: where are we now?. Clin Exp Ophthalmol 2002, 30:334-337.
205. Leonardi M, Pitchon EM, Bertsch A, et al. Wireless contact lens sensor for intraocular pressure monitoring: assessment on enucleated pig eyes. Acta Ophthalmol 2009, 87:433-437.
206. Leonardi M, Leuenberger P, Bertrand D, et al. First steps toward noninvasive intraocular pressure monitoring with a sensing contact lens. Invest Ophthalmol Vis Sci 2004, 45:3113-3117.
207. Kakaday T, Hewitt AW, Voelcker NH, et al. Advances in telemetric continuous intraocular pressure assessment. Br J Ophthalmol 2009, 93:992-996.
208. Stangel K, Kolnsberg S, Hammerschmidt D, et al. A programmable intraocular CMOS pressure sensor system implant. IEEE J Solid-State Circuits 2001, 36:1094-1100.
209. Walter P, Schnakenberg U, vom Bogel G, et al. Development of a completely encapsulated intraocular pressure sensor. Ophthalmic Res 2000, 32:278-284.
210. Chen P-J, Rodger DC, Humayan MS, et al. Unpowered sprial-tube parylene pressure sensor for intraocular pressure sensing. Sensors Actuators A 2006, 127:276-282.
211. Rizq RN, Choi WH, Eilers D, et al. Intraocular pressure measurement at the choroid surface: a feasibility study with implications for implantable microsystems. Br J Ophthalmol 2001, 85:868-871.
212. Chow EY, Yang CL, Chlebowski A, et al. Implantable wireless telemetry boards for in vivo transocular transmission. IEEE Trans Microwave Theory Techniques 2008, 56:3200-3208.
213. Prow TW, Bhutto I, Grebe R, et al. Nanoparticle-delivered biosensor for reactive oxygen species in diabetes. Vision Res 2008, 48:478-485.
214. Becerra SP Focus on Molecules: Pigment epithelium-derived factor (PEDF). Exp Eye Res 2006, 82:739-740.
215. Jones BW, Watt CB, Frederick JM, et al. Retinal remodeling triggered by photoreceptor degenerations. J Comp Neurol 2003, 464:1-16.
216. Milam AH, Li ZY, Fariss RN Histopathology of the human retina in retinitis pigmentosa. Prog Retin Eye Res 1998, 17:175-205.
217. Lakhanpal RR, Yanai D, Weiland JD, et al. Advances in the development of visual prostheses. Curr Opin Ophthalmol 2003, 14:122-127.
218. Chen SJ, Mahadevappa M, Roizenblatt R, et al. Neural responses elicited by electrical stimulation of the retina. Trans Am Ophthalmol Soc 2006, 104:252-259.
219. Zrenner E Will retinal implants restore vision?. Science 2002, 295:1022-1025.
220. Weiland JD, Liu W, Humayun MS Retinal prosthesis. Annu Rev Biomed Eng 2005, 7:361-401.
221. Choi SY, Sheng Z, Kramer RH Imaging light-modulated release of synaptic vesicles in the intact retina: retinal physiology at the dawn of the post-electrode era. Vision Res 2005, 45:3487-3495.
222. Nagel G, Szellas T, Huhn W, et al. Channelrhodopsin-2, a directly light-gated cation-selective membrane channel. Proc Natl Acad Sci U S A 2003, 100:13940-13945.
223. Bi A, Cui J, Ma YP, et al. Ectopic expression of a microbial-type rhodopsin restores visual responses in mice with photoreceptor degeneration. Neuron 2006, 50:23-33.
224. Lagali PS, Balya D, Awatramani GB, et al. Light-activated channels targeted to ON bipolar cells restore visual function in retinal degeneration. Nat Neurosci 2008, 11:667-675.
225. Tomita H, Sugano E, Yawo H, et al. Restoration of visual response in aged dystrophic RCS rats using AAV-mediated channelopsin-2 gene transfer. Invest Ophthalmol Vis Sci 2007, 48:3821-3826.
226. Bowes C, Li T, Danciger M, et al. Retinal degeneration in the rd mouse is caused by a defect in the beta subunit of rod cGMP-phosphodiesterase. Nature 1990, 347:677-680.
227. D'Cruz PM, Yasumura D, Weir J, et al. Mutation of the receptor tyrosine kinase gene Mertk in the retinal dystrophic RCS rat. Hum Mol Genet 2000, 9:645-651.
228. Ivanova E, Pan ZH Evaluation of the adeno-associated virus mediated long-term expression of channelrhodopsin-2 in the mouse retina. Mol Vis 2009, 15:1680-1689.
229. Wassle H Parallel processing in the mammalian retina. Nat Rev Neurosci 2004, 5:747-757.
230. Jacobs AL, Werblin FS Spatiotemporal patterns at the retinal output. J Neurophysiol 1998, 80:447-451.
231. Ivanova E, Hwang GS, Pan ZH, Troilo D Evaluation of AAV-mediated expression of Chop2-GFP in the marmoset retina. Invest Ophthalmol Vis Sci 2010, 51:5288-5296.
232. Dalkara D, Kolstad KD, Caporale N, et al. Inner limiting membrane barriers to AAV-mediated retinal transduction from the vitreous. Mol Ther 2009, 17:2096-2102.
233. Zhang Y, Ivanova E, Bi A, et al. Ectopic expression of multiple microbial rhodopsins restores ON and OFF light responses in retinas with photoreceptor degeneration. J Neurosci 2009, 29:9186-9196.
234. Doroudchi MM, Greenberg KP, Liu J, et al. Virally delivered channelrhodopsin-2 safely and effectively restores visual function in multiple mouse models of blindness. Mol Ther 2011.
235. Marc RE, Jones BW, Watt CB, et al. Extreme retinal remodeling triggered by light damage: implications for age related macular degeneration. Mol Vis 2008, 14:782-806.
236. Strettoi E, Pignatelli V, Rossi C, et al. Remodeling of second-order neurons in the retina of rd/rd mutant mice. Vision Res 2003, 43:867-877.
237. Gargini C, Terzibasi E, Mazzoni F, et al. Retinal organization in the retinal degeneration 10 (rd10) mutant mouse: a morphological and ERG study. J Comp Neurol 2007, 500:222-238.
238. Greenberg KP, Pham A, Werblin FS Differential targeting of optical neuromodulators to ganglion cell soma and dendrites allows dynamic control of center-surround antagonism. Neuron 2011, 69:713-720.
239. Busskamp V, Duebel J, Balya D, et al. Genetic reactivation of cone photoreceptors restores visual responses in retinitis pigmentosa. Science 2010, 329:413-417.
240. Fortin DL, Banghart MR, Dunn TW, et al. Photochemical control of endogenous ion channels and cellular excitability. Nat Method 2008, 5:331-338.
241. Caporale N, Kolstad KD, Lee T, et al. LiGluR restores visual responses in rodent models of inherited blindness. Mol Ther 2011, 19:1212-1219.
242. Pennisi CPJP, Zachar V, Greenbaum E, et al. Incorporation of photosynthetic reaction centers in the membrane of human cells: Toward a new tool for optical control of cell activity. Cell Mol Bioeng 2009, 2:156-165.
243. Kuritz T, Lee I, Owens ET, et al. Molecular photovoltaics and the photoactivation of mammalian cells. IEEE Trans Nanobiosci 2005, 4:196-200.
244. Pennisi CP, Greenbaum E, Yoshida K Spatial distribution of the electric potential from photosystem I reaction centers in lipid vesicles. IEEE Trans Nanobiosci 2008, 7:164-171.
245. Ahuja AK, Dorn JD, Caspi A, et al. Blind subjects implanted with the Argus II retinal prosthesis are able to improve performance in a spatial-motor task. Br J Ophthalmol 2011, 95:539-543.
246. Winter JO, Han N, Jensen R, et al. Adhesion molecules promote chronic neural interfaces following neurotrophin withdrawal. Conf Proc IEEE Eng Med Biol Soc 2009, 2009:7151-7154.
247. Kelly SK, Shire DB, Chen J, et al. Realization of a 15-channel, hermetically-encased wireless subretinal prosthesis for the blind. Conf Proc IEEE Eng Med Biol Soc 2009, 2009:200-203.
248. Zrenner E, Bartz-Schmidt KU, Benav H, et al. Subretinal electronic chips allow blind patients to read letters and combine them to words. Proc Biol Sci 2011, 278:1489-1497.
249. Julien S, Peters T, Ziemssen F, et al. Implantation of ultrathin, biofunctionalized polyimide membranes into the subretinal space of rats. Biomaterials 2011, 32:3890-3898.
250. Fujikado T, Kamei M, Sakaguchi H, et al. Testing of semichronically implanted retinal prosthesis by suprachoroidal-transretinal stimulation in patients with retinitis pigmentosa. Invest Ophthalmol Vis Sci 2011, 52:4726-4733.
251. Finlayson PG, Iezzi R Glutamate stimulation of retinal ganglion cells in normal and s334ter-4 rat retinas: a candidate for a neurotransmitter-based retinal prosthesis. Invest Ophthalmol Vis Sci 2010, 51:3619-3628.
252. Kotov NA, Winter JO, Jan E, et al. Nanomaterials for neural interfaces. Adv Mater 2009, 21:3970-4004.
253. Lovric J, Bazzi HS, Cuie Y, et al. Differences in subcellular distribution and toxicity of green and red emitting CdTe quantum dots. J Mol Med 2005, 83:377-385.
254. Chan WH, Shiao NH, Lu PZ CdSe quantum dots induce apoptosis in human neuroblastoma cells via mitochondrial-dependent pathways and inhibition of survival signals. Toxicol Lett 2006, 167:191-200.
255. Choi AO, Cho SJ, Desbarats J, et al. Quantum dot-induced cell death involves Fas upregulation and lipid peroxidation in human neuroblastoma cells. J Nanobiotechnol 2007, 5:1.
256. Maysinger D, Behrendt M, Lalancette-Hebert M, et al. Real-time imaging of astrocyte response to quantum dots: in vivo screening model system for biocompatibility of nanoparticles. Nano Lett 2007, 7:2513-2520.
257. Oberdorster E Manufactured nanomaterials (fullerenes, C60) induce oxidative stress in the brain of juvenile largemouth bass. Environ Health Perspect 2004, 112:1058-1062.
258. Kim DH, Martin DC Sustained release of dexamethasone from hydrophilic matrices using PLGA nanoparticles for neural drug delivery. Biomaterials 2006, 27:3031-3037.
259. Bharali DJ, Klejbor I, Stachowiak EK, et al. Organically modified silica nanoparticles: a nonviral vector for in vivo gene delivery and expression in the brain. Proc Natl Acad Sci U S A 2005, 102:11539-11544.
260. Zou LL, Huang L, Hayes RL, et al. Liposome-mediated NGF gene transfection following neuronal injury: potential therapeutic applications. Gene Ther 1999, 6:994-1005.
261. Green RA, Lovell NH, Wallace GG, et al. Conducting polymers for neural interfaces: challenges in developing an effective long-term implant. Biomaterials 2008, 29:3393-3399.
262. Abidian MR, Kim D-H, Martin DC Conducting-polymer nanotubes for controlled drug release. Adv Mater 2006, 18:405-409.
263. Kim D-H, Richardson-Burns SM, Hendricks JL, et al. Effect of immobilized nerve growth factor on conductive polymers: electrical properties and cellular responses. Adv Functional Mater 2007, 17:79-86.
264. Cui X, Lee VA, Raphael Y, et al. Surface modification of neural recording electrodes with conducting polymer/biomolecule blends. J Biomed Mater Res 2001, 56:261-272.
265. Decher G Fuzzy nanoassemblies: toward layered polymeric multicomposites. Science 1997, 277:1232-1237.
266. Gheith MK, Pappas TC, Lioppo AV, et al. Stimulation of neural cells by lateral currents in conductive layer-by-layer films of single-walled carbon nanotubes. Adv Mater 2006, 18:2975-2979.
267. Sinani VA, Koktysh DS, Yun B-G, et al. Collagen coating promotes biocompatibility of semiconductor nanoparticles in stratified LBL films. Nano Lett 2003, 3:1177-1183.
268. Pappas TC, Wickramanyake WM, Jan E, et al. Nanoscale engineering of a cellular interface with semiconductor nanoparticle films for photoelectric stimulation of neurons. Nano Lett 2007, 7:513-519.
269. Rama P, Matuska S, Paganoni G, et al. Limbal stem-cell therapy and long-term corneal regeneration. N Engl J Med 2010, 363:147-155.
270. Lewis GP, Linberg KA, Fisher SK Neurite outgrowth from bipolar and horizontal cells after experimental retinal detachment. Invest Ophthalmol Vis Sci 1998, 39:424-434.
271. Lamba DA, Gust J, Reh TA Transplantation of human embryonic stem cell-derived photoreceptors restores some visual function in Crx-deficient mice. Cell Stem Cell 2009, 4:73-79.
272. Lamba DA, Karl MO, Reh TA Strategies for retinal repair: cell replacement and regeneration. Prog Brain Res 2009, 175:23-31.
273. Lamba DA, Karl MO, Ware CB, et al. Efficient generation of retinal progenitor cells from human embryonic stem cells. Proc Natl Acad Sci U S A 2006, 103:12769-12774.
274. Lamba DA, McUsic A, Hirata RK, et al. Generation, purification and transplantation of photoreceptors derived from human induced pluripotent stem cells. PLoS ONE 2010, 5:e8763.
275. Ikeda H, Osakada F, Watanabe K, et al. Generation of Rx+/Pax6+ neural retinal precursors from embryonic stem cells. Proc Natl Acad Sci U S A 2005, 102:11331-11336.
276. Osakada F, Ikeda H, Mandai M, et al. Toward the generation of rod and cone photoreceptors from mouse, monkey and human embryonic stem cells. Nat Biotechnol 2008, 26:215-224.
277. Hirami Y, Osakada F, Takahashi K, et al. Generation of retinal cells from mouse and human induced pluripotent stem cells. Neurosci Lett 2009, 458:126-131.
278. Osakada F, Jin ZB, Hirami Y, et al. In vitro differentiation of retinal cells from human pluripotent stem cells by small-molecule induction. J Cell Sci 2009, 122:3169-3179.
279. Meyer JS, Katz ML, Maruniak JA, et al. Embryonic stem cell-derived neural progenitors incorporate into degenerating retina and enhance survival of host photoreceptors. Stem Cells 2006, 24:274-283.
280. Seiler MJ, Aramant RB, Thomas BB, et al. Visual restoration and transplant connectivity in degenerate rats implanted with retinal progenitor sheets. Eur J Neurosci 2010, 31:508-520.
281. MacLaren RE, Pearson RA, MacNeil A, et al. Retinal repair by transplantation of photoreceptor precursors. Nature 2006, 444:203-207.
282. Gust J, Reh TA Adult donor rod photoreceptors integrate into the mature mouse retina. Invest Ophthalmol Vis Sci. 2011.
283. Tomita M, Lavik E, Klassen H, et al. Biodegradable polymer composite grafts promote the survival and differentiation of retinal progenitor cells. Stem Cells 2005, 23:1579-1588.
284. Karl MO, Reh TA Regenerative medicine for retinal diseases: activating endogenous repair mechanisms. Trends Mol Med 2010, 16:193-202.
285. Pot SA, Liliensiek SJ, Myrna KE, et al. Nanoscale topography-induced modulation of fundamental cell behaviors of rabbit corneal keratocytes, fibroblasts, and myofibroblasts. Invest Ophthalmol Vis Sci 2010, 51:1373-1381.
286. Sugino IK, Gullapalli VK, Sun Q, et al. Cell-deposited matrix improves retinal pigment epithelium survival on aged submacular human Bruch's membrane. Invest Ophthalmol Vis Sci 2011, 52:1345-1358.
287. Scadden DT The stem-cell niche as an entity of action. Nature 2006, 441:1075-1079.
288. 2 nanotube diameter directs cell fate. Nano Lett 2007, 7:1686-1691.
289. Chua KN, Chai C, Lee PC, et al. Surface-aminated electrospun nanofibers enhance adhesion and expansion of human umbilical cord blood hematopoietic stem/progenitor cells. Biomaterials 2006, 27:6043-6051.
290. Dalby MJ, McCloy D, Robertson M, et al. Osteoprogenitor response to defined topographies with nanoscale depths. Biomaterials 2006, 27:1306-1315.
291. Steedman MR, Tao SL, Klassen H, et al. Enhanced differentiation of retinal progenitor cells using microfabricated topographical cues. Biomed Microdevices 2010, 12:363-369.
292. Recknor JB, Sakaguchi DS, Mallapragada SK Directed growth and selective differentiation of neural progenitor cells on micropatterned polymer substrates. Biomaterials 2006, 27:4098-4108.
293. Mooney DJ, Vandenburgh H Cell delivery mechanisms for tissue repair. Cell Stem Cell 2008, 2:205-213.
294. Silva GA, Czeisler C, Niece KL, et al. Selective differentiation of neural progenitor cells by high-epitope density nanofibers. Science 2004, 303:1352-1355.
295. Ellis-Behnke RG, Liang YX, You SW, et al. Nano neuro knitting: peptide nanofiber scaffold for brain repair and axon regeneration with functional return of vision. Proc Natl Acad Sci U S A 2006, 103:5054-5059.
296. Hynes SR, Lavik EB A tissue-engineered approach towards retinal repair: scaffolds for cell transplantation to the subretinal space. Graefes Arch Clin Exp Ophthalmol 2010, 248:763-778.
297. Lavik EB, Klassen H, Warfvinge K, et al. Fabrication of degradable polymer scaffolds to direct the integration and differentiation of retinal progenitors. Biomaterials 2005, 26:3187-3196.
298. Redenti S, Tao S, Yang J, et al. Retinal tissue engineering using mouse retinal progenitor cells and a novel biodegradable, thin-film poly(e-caprolactone) nanowire scaffold. J Ocul Biol Dis Infor 2008, 1:19-29.
299. Sodha S, Wall K, Redenti S, et al. Microfabrication of a three-dimensional polycaprolactone thin-film scaffold for retinal progenitor cell encapsulation. J Biomat Sci 2011, 22:443-456.
300. Tao SL, Desai TA Micromachined devices: the impact of controlled geometry from cell-targeting to bioavailability. J Controlled Release 2005, 109:127-138.
301. Sacconi L, O'Connor RP, Jasaitis A, et al. In vivo multiphoton nanosurgery on cortical neurons. J Biomed Optics 2007, 12:050502.
302. Ellis-Behnke RG, Teather LA, Schneider GE, et al. Using nanotechnology to design potential therapies for CNS regeneration. Curr Pharm Design 2007, 13:2519-2528.
303. Wang BG, Halbhuber KJ Corneal multiphoton microscopy and intratissue optical nanosurgery by nanojoule femtosecond near-infrared pulsed lasers. Ann Anat 2006, 188:395-409.
304. Leary SP, Liu CY, Apuzzo ML Toward the emergence of nanoneurosurgery: part III - nanomedicine: targeted nanotherapy, nanosurgery, and progress toward the realization of nanoneurosurgery. Neurosurgery 2006, 58:1009-1026. discussion-26.
305. Fankhauser F, Niederer PF, Kwasniewska S, et al. Supernormal vision, high-resolution retinal imaging, multiphoton imaging and nanosurgery of the cornea - a review. Technol Health Care 2004, 12:443-453.
306. Konig K Robert Feulgen Prize Lecture. Laser tweezers and multiphoton microscopes in life sciences. Histochem Cell Biol 2000, 114:79-92.
307. Kim P, Lieber CM Nanotube nanotweezers. Science 1999, 286:2148-2150.
308. Bhisitkul RB, Keller CG Development of microelectromechanical systems (MEMS) forceps for intraocular surgery. Br J Ophthalmol 2005, 89:1586-1588.
309. Zhang LW, Monteiro-Riviere NA Mechanisms of quantum dot nanoparticle cellular uptake. Toxicol Sci 2009, 110:138-155.
310. Hoet P, Legiest B, Geys J, et al. Do nanomedicines require novel safety assessments to ensure their safety for long-term human use?. Drug Saf 2009, 32:625-636.
311. Magrez A, Kasas S, Salicio V, et al. Cellular toxicity of carbon-based nanomaterials. Nano Lett 2006, 6:1121-1125.
312. Zhu L, Chang DW, Dai L, et al. DNA damage induced by multiwalled carbon nanotubes in mouse embryonic stem cells. Nano Lett 2007, 7:3592-3597.